Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.

Balgobind BV, Lugthart S, Hollink IH, Arentsen-Peters ST, van Wering ER, de Graaf SS, Reinhardt D, Creutzig U, Kaspers GJ, de Bont ES, Stary J, Trka J, Zimmermann M, Beverloo HB, Pieters R, Delwel R, Zwaan CM, van den Heuvel-Eibrink MM.

Leukemia. 2010 May;24(5):942-9. doi: 10.1038/leu.2010.47.

PMID:
20357826
2.

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ, Beverloo HB, Löwenberg B, Delwel R.

Blood. 2008 Apr 15;111(8):4329-37. doi: 10.1182/blood-2007-10-119230.

3.

Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.

Haferlach C, Bacher U, Grossmann V, Schindela S, Zenger M, Kohlmann A, Kern W, Haferlach T, Schnittger S.

Genes Chromosomes Cancer. 2012 Dec;51(12):1079-85. doi: 10.1002/gcc.21992.

PMID:
22887804
4.
5.

Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.

Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Löwenberg B, Döhner K, Döhner H, Delwel R.

J Clin Oncol. 2013 Jan 1;31(1):95-103. doi: 10.1200/JCO.2011.41.5505.

PMID:
23008312
6.

Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.

Haas K, Kundi M, Sperr WR, Esterbauer H, Ludwig WD, Ratei R, Koller E, Gruener H, Sauerland C, Fonatsch C, Valent P, Wieser R.

Genes Chromosomes Cancer. 2008 Apr;47(4):288-98. doi: 10.1002/gcc.20532.

PMID:
18181178
7.

Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption.

Meyer S, Fergusson WD, Whetton AD, Moreira-Leite F, Pepper SD, Miller C, Saunders EK, White DJ, Will AM, Eden T, Ikeda H, Ullmann R, Tuerkmen S, Gerlach A, Klopocki E, Tönnies H.

Genes Chromosomes Cancer. 2007 Apr;46(4):359-72.

PMID:
17243162
8.

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, Verhoef G, Verdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Löwenberg B, Delwel R.

Blood. 2003 Feb 1;101(3):837-45.

9.

High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.

Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF, Lübbert M, Ossenkoppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner K, Delwel R.

J Clin Oncol. 2010 Apr 20;28(12):2101-7. doi: 10.1200/JCO.2009.26.0646.

PMID:
20308656
10.

Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.

Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H.

J Clin Oncol. 2010 Aug 20;28(24):3890-8. doi: 10.1200/JCO.2010.29.2771.

PMID:
20660833
11.

Acute panmyelosis with myelofibrosis with EVI1 amplification.

Grygalewicz B, Woroniecka R, Pastwińska A, Rygier J, Krawczyk P, Borg K, Makuch-Łasica H, Patkowska E, Pieńkowska-Grela B.

Cancer Genet. 2012 May;205(5):255-60. doi: 10.1016/j.cancergen.2012.02.003.

PMID:
22682625
12.

Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.

Vázquez I, Maicas M, Cervera J, Agirre X, Marin-Béjar O, Marcotegui N, Vicente C, Lahortiga I, Gomez-Benito M, Carranza C, Valencia A, Brunet S, Lumbreras E, Prosper F, Gómez-Casares MT, Hernández-Rivas JM, Calasanz MJ, Sanz MA, Sierra J, Odero MD.

Haematologica. 2011 Oct;96(10):1448-56. doi: 10.3324/haematol.2011.040535.

13.

The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.

Lo Coco F, Pisegna S, Diverio D.

Haematologica. 1997 May-Jun;82(3):364-70. Review.

14.

A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.

Storlazzi CT, Anelli L, Albano F, Zagaria A, Ventura M, Rocchi M, Panagopoulos I, Pannunzio A, Ottaviani E, Liso V, Specchia G.

Ann Hematol. 2004 Feb;83(2):78-83.

PMID:
14551738
15.

High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML.

Jo A, Mitani S, Shiba N, Hayashi Y, Hara Y, Takahashi H, Tsukimoto I, Tawa A, Horibe K, Tomizawa D, Taga T, Adachi S, Yoshida T, Ichikawa H.

Leukemia. 2015 May;29(5):1076-83. doi: 10.1038/leu.2015.5.

PMID:
25567132
16.

Review: Aberrant EVI1 expression in acute myeloid leukaemia.

Hinai AA, Valk PJ.

Br J Haematol. 2016 Mar;172(6):870-8. doi: 10.1111/bjh.13898. Review.

PMID:
26729571
17.

DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome.

Levy ER, Parganas E, Morishita K, Fichelson S, James L, Oscier D, Gisselbrecht S, Ihle JN, Buckle VJ.

Blood. 1994 Mar 1;83(5):1348-54.

18.

Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.

Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, Ihle J, Taetle R.

Blood. 1994 Aug 15;84(4):1243-8.

19.

An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies.

Bobadilla D, Enriquez EL, Alvarez G, Gaytan P, Smith D, Slovak ML.

Br J Haematol. 2007 Mar;136(6):806-13.

PMID:
17341266
20.

High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.

Ho PA, Alonzo TA, Gerbing RB, Pollard JA, Hirsch B, Raimondi SC, Cooper T, Gamis AS, Meshinchi S.

Br J Haematol. 2013 Sep;162(5):670-7. doi: 10.1111/bjh.12444.

Items per page

Supplemental Content

Support Center